Sparks Location

Skin Cancer and Dermatology Institute

Hidradenitis Suppurativa

Skin Diseases

Hidradenitis

Bacterial Skin Diseases

Acne Vulgaris

Dermatitis

Sweat Gland Diseases

Zura Bio Inc

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Skin Cancer and Dermatology Institute | Sparks Location

Site insights

Work at this site?

Active trials

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)

Trial sponsors